Kadmon Holdings Inc (NYSE:KDMN)’s share price traded down 5.4% during mid-day trading on Monday . The stock traded as low as $4.09 and last traded at $4.24. 528,491 shares were traded during trading, a decline of 52% from the average session volume of 1,108,311 shares. The stock had previously closed at $4.48.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Kadmon from a “strong sell” rating to a “hold” rating in a report on Saturday, March 10th. Piper Jaffray Companies reiterated a “positive” rating and issued a $9.00 target price (up previously from $7.00) on shares of Kadmon in a research report on Tuesday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research report on Friday, March 9th. Finally, Jefferies Group upped their target price on Kadmon to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 13th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.21.
The company has a market capitalization of $352.32, a PE ratio of -2.85 and a beta of 5.59.
A number of hedge funds and other institutional investors have recently modified their holdings of KDMN. Goldman Sachs Group Inc. purchased a new stake in Kadmon in the second quarter valued at approximately $114,000. Bank of New York Mellon Corp purchased a new stake in Kadmon in the 3rd quarter worth approximately $119,000. Old West Investment Management LLC purchased a new stake in Kadmon in the 3rd quarter worth approximately $169,000. Wells Fargo & Company MN boosted its position in Kadmon by 17.0% in the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares in the last quarter. Finally, BlueCrest Capital Management Ltd purchased a new stake in Kadmon in the 4th quarter worth approximately $241,000. Hedge funds and other institutional investors own 61.71% of the company’s stock.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.